CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...